MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
14.27
-0.13 (-0.90%)
At close: Sep 15, 2025, 4:00 PM EDT
14.45
+0.18 (1.26%)
After-hours: Sep 15, 2025, 4:59 PM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 8 or -25.81% compared to the previous year.
Employees
23
Change (1Y)
-8
Growth (1Y)
-25.81%
Revenue / Employee
n/a
Profits / Employee
-$490,180
Market Cap
64.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INKT News
- 4 weeks ago - MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results - GlobeNewsWire
- 6 weeks ago - MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - GlobeNewsWire
- 2 months ago - Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? - Benzinga
- 3 months ago - MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - GlobeNewsWire
- 3 months ago - MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients - GlobeNewsWire
- 4 months ago - MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript - Seeking Alpha